India Pharma Outlook Team | Monday, 24 August 2026
The latest drug recall by Sun Pharmaceutical Industries has drawn attention to a manufacturing quality issue involving its epilepsy medicine carbamazepine.
The company is voluntarily recalling 1,968 bottles of the anticonvulsant after consumers reported black spots on tablets.
Sun Pharma began the recall following a complaint about black specks. The company later identified cGMP deviations linked to the manufacturing process as the underlying cause.
The affected batch came from Taro Pharmaceutical’s Haifa Bay facility in Israel. The US FDA classified the action as a Class II recall, indicating potential temporary or medically reversible health consequences.
The immediate trigger for the Sun Pharma drug recall came from a complaint about black specks on carbamazepine tablets. Sun Pharma received the complaint and initiated the recall on August 3. The company later traced the issue to burnt excipient used during manufacturing. The finding led Sun Pharma to identify cGMP deviations as the underlying cause.
The affected product contains carbamazepine, an anticonvulsant used to manage epilepsy. Doctors also prescribe the medicine for nerve pain such as trigeminal neuralgia. It also has applications in treating bipolar disorders. The recall therefore centers on a specific manufacturing quality issue rather than a new safety concern associated with carbamazepine as a medicine.
Also Read: How Can Indian Pharma Strengthen Quality Amid Rising FDA Scrutiny
The affected batch came from Taro Pharmaceutical’s Haifa Bay facility in Israel. Taro operates as a wholly owned subsidiary of Sun Pharma. The manufacturing link makes the drug recall relevant to pharmaceutical quality systems across Sun Pharma’s global operations. The company must ensure that manufacturing processes meet cGMP requirements across facilities supplying regulated markets.
In this case, the company identified deviations within the manufacturing process after investigating the complaint. The recall allows the affected product to leave the US market while the company addresses the quality issue.
The USFDA classified the carbamazepine recall as a Class II recall. Under this category, the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences. The FDA also considers the probability of serious adverse health consequences remote.
The classification provides important context for the latest USFDA recall. It does not indicate that the affected product will necessarily cause serious harm. Instead, it reflects the FDA's assessment of the potential risk associated with the identified quality issue.
The latest drug recall adds another quality control event to the regulatory landscape for Sun Pharma's US business. The company has identified the manufacturing deviation and initiated corrective action through the recall.
The incident also highlights the importance of cGMP controls in pharmaceutical manufacturing. Small physical defects, such as visible black spots, can trigger investigations and regulatory action when they affect finished drug products.
For Sun Pharma, the immediate focus remains on addressing the manufacturing deviation and maintaining product quality across its US supply chain. The Sun Pharma drug recall involves 1,968 bottles and remains classified as a Class II action by the FDA.
